Use of (e)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of alzheimer's disease
CA 2135752 C · Owner: Merrell Pharmaceuticals Inc. · Inventors: Palfreyman, Michael G.; Mcdonald, Ian A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a method of treatment for Alzheimer's disease in a patient in need thereof comprising administering to said patient a therapeutically effective amount of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine or a pharmaceutically acceptable salt thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 14, 1993 and granted July 14, 1998. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 14, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 14, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.